Anthrax Vaccines Market To Reach USD 863.7 Million By 2026 | Reports And Data


Increasing prevalence of Anthrax disease is most significant factor estimated to stimulate market demand.

Market Size – USD 465.5 million in 2018, Market Growth - CAGR of 7.4%, Market Trends – Increase in industrial processing of contaminated materials

NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- The global Anthrax Vaccines Market is expected to reach USD 863.7 million by 2026, according to a new report by Reports and Data. The market is stimulated by increasing prevalence of infectious diseases like anthrax worldwide. Besides, the cost-effectiveness of immunizations, new investments opportunities from government, research foundations, donors, advances in research and manufacturing technologies is anticipated to fuel the market growth in the forecast period. Additionally, the presence of large target population in developing markets is driving the market growth.

Nevertheless, lack of awareness, cost-prohibitive vaccination in under-developed nations, scarcity of availability and affordability, strict regulatory norms are the factors which may hamper the market growth in the upcoming years.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/1357

An increase in the eating of undercooked meat from infected with the disease is causative of the growth of the market. Also, an increase in industrial processing of contaminated materials like hides and hair wool among others is expected to support the market growth in the future.

The markets in the Asia Pacific and Latin America region are projected to witness significant growth in the forecast period. Developing countries like China and India are likely to drive the market demand in the Asia Pacific region in the upcoming years attributed to economic growth, improved health care infrastructure, increase in the number of insurance payers, growth of the private health care sector, and growing awareness for healthy well-being in these nations.

Further key findings from the report suggest

  • Cell-Free PA vaccines contributed to the largest market share with around 60% of the market share in 2018 and are expected to witness a growth rate of 7.6% during the forecast period. In comparison to AVA, the British AVP consists of lower levels of PA and higher concentrations of additional Bacillus anthracis antigens, including edema factor (EF), lethal factor (LF), and specific bacillus surface proteins. These enhanced components in the British AVP anthrax vaccines may provide a slight improvement in protection against anthrax.
  • Anthrax vaccines are primarily used for providing vaccination to animals. Application of these vaccines for animal use dominated the market with a market share of more than 90% in 2018 and is expected to grow at a CAGR of 7.3% in the period 2019-2026.

To identify the key trends in the industry, click on the link below:   https://www.reportsanddata.com/report-detail/anthrax-vaccines-market

  • The market in North America held the largest market share in 2018 and is estimated to have a CAGR of 7.1% during the forecast period.
  • Key participants include Merck & Co. Inc., Emergent Bio-Solutions, Zoetis Inc., PharmaAthene Inc., Biogenesis Bago Inc., Porton Biopharma Inc., Colorado Serum, Merial, Intervac, and Vecol among others.
  • In July 2018, the advisory committee on Immunization Practices chose to approve recommendations for the usage of Anthrax Vaccine Adsorbed (AVA) in post-exposure prophylaxis (PEP) in the occurrence of a widespread release of Bacillus anthracis spores.

Order Now: https://www.reportsanddata.com/checkout-form/1357

Segments covered in the report:

For the purpose of this report, Reports and Data have segmented global anthrax vaccines market on the basis of product type, application, end-user, and region:

Product Type Outlook (Revenue, USD Million; 2016-2026)

  • Cell-Free PA Vaccines
    • Anthrax Vaccine Adsorbed (AVA)
    • Anthrax Vaccine Precipitated (AVP)
  • Live Cells

Application Outlook (Revenue, USD Million; 2016-2026)

  • Human Use
  • Animal Use

End-user Outlook (Revenue, USD Million; 2016-2026)

  • Hospitals
  • Clinics
  • Vaccination Centers
  • Others

Regional Outlook (Volume, Kilo Tons; Revenue, USD Billion; 2018-2026)

  • North America
    • U.S.
  • Europe
    • UK
    • France
  • Asia Pacific
    • China
    • India
    • Japan
  • MEA
  • Latin America
    • Brazil

Browse more reports of Pharmaceutical category at:  https://www.reportsanddata.com/report/category/pharmaceutical

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John Watson

Head of Business Development

Reports And Data | Web: www.reportsanddata.com

Direct Line: +1-800-819-3052

E-mail: sales@reportsanddata.com